Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416785 | 1.00 | PARP1 (0.73) | PARP1 | |
| SCHEMBL28377366 | 0.88 | PARP1 (0.73) | PARP1 | |
| SCHEMBL19005828 | 0.86 | PARP1 (0.70) | PARP1 | |
| SCHEMBL28378754 | 0.85 | PARP1 (0.69) | PARP1 | |
| SCHEMBL10039764 | 0.84 | PARP1 (0.74) | PARP1 | |
| Fluzoparib SCHEMBL29361923 | 0.84 | PARP1 (1.00) | PARP1 | |
| Fluzoparib SCHEMBL30641389 | 0.84 | PARP1 (1.00) | PARP1 | |
| Fluzoparib SCHEMBL10025553 | 0.84 | PARP1 (1.00) | PARP1 | |
| SCHEMBL30888480 | 0.84 | PARP1 (1.00) | PARP1 | |
| SCHEMBL10025550 | 0.84 | PARP1 (1.00) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111732594-B | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-111732594-A | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| EP-2604610-B1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| EP-2604610-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) | 2013-06-19 | — | — | EP | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| WO-2012019427-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | PARP1, PARP2, PARP3 | PARP1 1/4885 |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PARP1, PARP2, PARP4 | PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.